Clinical trial
Study Evaluating HKI-272 in Tumors
NCT00146172 · Puma Biotechnology, Inc., Industry · Completed
Key facts
| NCT number | NCT00146172 |
|---|---|
| Title | Study Evaluating HKI-272 in Tumors |
| Official title | An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors |
| Lead sponsor | Puma Biotechnology, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | neratinib |
| Enrollment | 73 |
| Start date | Nov 1, 2003 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 5, 2005 |
| Last update posted | Sep 17, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: